The global medical technology industry is one of healthcare’s most dynamic sectors, blending engineering, biology, and increasingly, artificial intelligence, to keep people alive and improve quality of life. The global medical device market reached roughly $584–586 billion in 2025 and is projected to climb toward $623 billion in 2026, with long-range forecasts putting the industry above $1 trillion by the mid-2030s. Here’s a look at the companies leading that charge, along with the trends reshaping the competitive landscape.
1. Medtronic (United States)
Medtronic remains the world’s largest pure-play medical device company, with medical device segment revenue in the range of $33–36 billion. It operates across four major business units — cardiovascular, neuroscience, medical-surgical, and diabetes — and employs roughly 95,000 people in more than 140 countries. The company’s cardiovascular business has been a standout performer, powered by pulsed-field ablation systems used to treat atrial fibrillation, while its neuroscience unit continues to advance adaptive deep brain stimulation technology.
Medtronic is also in the middle of a major structural shift: it’s spinning off its diabetes business — worth about $2.8 billion in annual revenue — into a newly independent, publicly traded company called MiniMed, which launched its IPO in February 2026 at a valuation of roughly $7.86 billion. That move could eventually allow Johnson & Johnson MedTech to overtake Medtronic in next year’s revenue rankings.
2. Johnson & Johnson MedTech (United States)
J&J’s MedTech division makes up more than a third of the company’s overall revenue and spans orthopedics (through DePuy Synthes), surgery (Ethicon), cardiovascular devices (Biosense Webster), and vision care. With medical device revenue approaching $34 billion, J&J is positioned to potentially claim the industry’s top spot once Medtronic’s diabetes spinoff is finalized.
3. Abbott Laboratories (United States)
Abbott sits at the intersection of devices and diagnostics, with particular strength in cardiovascular care, continuous glucose monitoring (CGM), and structural heart devices. Its business model leans on building platforms — devices paired with consumables and patient workflows — that create long adoption cycles and recurring revenue. In 2026, Abbott has continued to expand its cardiac monitoring portfolio and reported strong early clinical results for its investigational left atrial appendage occluder for atrial fibrillation patients.
4. Siemens Healthineers (Germany)
One of the giants of diagnostic imaging, Siemens Healthineers generates around $27 billion in revenue and competes directly with GE HealthCare and Philips in imaging and diagnostics. The company has faced some headwinds from softer demand in China and currency volatility affecting the dollar value of its European earnings, but it remains a dominant force in enterprise imaging and laboratory diagnostics.
5. Stryker (United States)
Stryker has been one of the industry’s fastest-growing large-cap players, fueled by an active acquisition strategy in orthopedics, neurotech, and medical-surgical products. Recent moves include the roughly $4.9 billion purchase of thrombectomy device maker Inari Medical, alongside a strategic exit from the spinal implants business to sharpen its focus on higher-growth segments.
6. Boston Scientific (United States)
Boston Scientific has climbed back into the industry’s top ten through a mix of organic growth and consistent tuck-in acquisitions, with particular strength in interventional cardiology and endoscopy. Its growth rate has outpaced much of the broader medtech sector, illustrating how a focused strategy can compete with — and sometimes outgrow — larger, more diversified rivals.
7. GE HealthCare (United States)
Spun off from General Electric, GE HealthCare focuses on medical imaging, diagnostics, and patient monitoring equipment, building on a company history that stretches back to 1893. Like Siemens Healthineers, it has had to navigate softer demand in the Chinese market in recent reporting periods.
8. Philips (Netherlands)
Following the sale of its personal health division in late 2024, Philips is now a fully dedicated health technology company. Its portfolio includes more than 450 types of medical equipment, from MRI scanners to diagnostic ECG devices, and its healthcare business now represents the entirety of its revenue base.
9. Roche Diagnostics (Switzerland)
While Roche is best known as a pharmaceutical giant, its diagnostics division is a major force in the medtech world in its own right, generating seventeen billion dollars or more annually and holding a dominant position in in-vitro diagnostics (IVD). The broader IVD sector has returned to steady core growth now that pandemic-era testing demand has normalized.
10. Zimmer Biomet (United States)
A leader in orthopedics, Zimmer Biomet specializes in joint replacement, surgical robotics, and musculoskeletal solutions. The company continues to expand its ROSA robotic knee system and has invested in digital tools that let clinicians track patient recovery remotely.
Other Notable Players
Several additional companies round out the industry’s upper tier:
- Intuitive Surgical, the long-time leader in soft-tissue surgical robotics;
- Becton Dickinson, a major force in medical supplies and diagnostics;
- Dexcom, a leader in continuous glucose monitoring that has been expanding into AI-driven health insights;
- Smith+Nephew, a UK-based specialist in orthopedics and wound care;
- ResMed, which drives innovation in sleep apnea and home-based respiratory care;
- B. Braun, a family-owned German company with more than 180 years of history in medical devices.
Key Trends Shaping the Industry in 2026
Consolidation and portfolio optimization. Large players continue to acquire smaller, high-growth companies while divesting slower-growth business lines — Stryker’s Inari acquisition paired with its spinal implant exit is a clear example of this pattern playing out across the sector.
Surgical robotics expansion. Once dominated almost exclusively by Intuitive Surgical, the soft-tissue robotics space is now seeing new entrants — Medtronic’s Hugo system received FDA clearance for urologic procedures in 2025, marking its entry into a market long controlled by a single player.
AI and connected care. From smart continuous glucose monitors to AI-supported clinical decision-making tools, artificial intelligence is increasingly embedded directly into medical devices rather than bolted on as an afterthought.
Shift toward outpatient and home-based care. More than a trillion dollars in annual healthcare spending is expected to migrate toward digital, data-enabled, and patient-centered care models, with remote monitoring and home-based care becoming standard rather than exceptional.
Regional shifts. North America still commands roughly 40% of the global medtech market, but Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and rising government investment.
Regulatory complexity. Europe’s Medical Device Regulation (MDR) has raised the cost and complexity of compliance, which tends to favor large, well-resourced incumbents over smaller challengers trying to enter the market.
The Bottom Line
The medtech industry in 2026 is defined by a productive tension between scale and speed. The largest companies bring capital, global regulatory relationships, and installed customer bases that are difficult to replicate — but that same size can create organizational inertia. Meanwhile, more focused competitors are proving that a sharper strategy can generate growth rates well above the sector average. As AI, robotics, and connected diagnostics continue to reshape clinical workflows, the companies that combine financial scale with genuine agility are the ones most likely to define the industry’s next decade.
